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SUMMARy – Thyroid cancer (tC) is the most common endocrine cancer today. The rising inci-
dence of the differentiated papillary type cannot be entirely explained by early and meticulous diag-
nosis, since a proportion of large tumors has also been reported. in this review, we present the results 
of numerous investigations focused on possible factors causing increased tC incidence, such as chro-
mosomal and genetic alterations, iodine intake, tSh level, autoimmune thyroid disease, gender, estro-
gen, obesity, lifestyle changes, and environmental pollutants. Up to now, only childhood exposure to 
ionizing radiation has been fully recognized as a risk factor. There is also a possibility that yet undis-
covered carcinogens, especially during intrauterine life or early childhood, might be responsible for 
increased tC incidence as well as epigenetic changes. Therefore, more studies are necessary in order to 
further investigate the potential risk factors for tC and their mechanisms of action.
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Introduction
Thyroid cancer (tC) is the most common endo-
crine cancer today1,2. The two main differentiated 
forms are the papillary (PtC) and follicular types 
(FtC). Medullary thyroid cancer (MtC) originates 
from calcitonin secreting C cells and is present in 
3-5% of all thyroid cancers. Anaplastic thyroid cancer 
(AtC) is uncommon but highly aggressive1,3.
tC incidence has increased all over the world in 
the last three decades1,4. it is believed that improved 
detection of cancers in the preclinical stage has con-
tributed to this increase4, but evidence also suggest a 
higher true incidence, since an increase in the number 
of large tumors, especially papillary thyroid cancer, has 
been reported, without significant change in the fol-
licular and medullary histotypes5. The incidence of 
anaplastic tC has decreased6. Mortality from tC, de-
spite earlier diagnosis and better treatment, has not 
decreased4. Therefore, a true increase could indeed be 
due to early and more sensitive diagnostics but could 
also be a consequence of population exposure to exter-
nal factors such as radiation, harmful chemical sub-
stances, and carcinogens present in the environment4, 
or it might be multifactorial.
Although the precise causes of tC are still un-
known, many studies have searched for possible risk 
factors; an attempt to review and summarize these fac-
tors is presented in this paper (table 1).
Potential risk factors for thyroid cancer
Chromosomal (genetic) alterations
it seems that the activation of the mitogen-activat-
ed protein kinases (MAPk) and phosphoinositide 3 
kinase-Akt (Pi3k-Akt) signaling pathways might 
have a role in thyroid cancer growth1. in papillary thy-
roid cancer, activation of the MAPk signaling path-
way occurs through two main mechanisms: recombi-
nation events and point mutations which are found in 
almost 70% of papillary cancers1. Chromosomal rear-
rangements such as rearrangement during transfection 
of proto-oncogene/papillary thyroid cancer (Ret/
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PtC), PAX8/PPARγ, and B-type Raf kinase/A-kinase 
anchor protein 9 (BRAF/AkAP9) have been associ-
ated with exposure to ionizing radiation and likely 
represent fragile sites on the chromosome. Point mu-
tations (RAS and BRAF genes) are most likely result 
of environmentally-induced or stochastic mutagene-
sis1. on the other hand, mutated RAS oncogene and 
PAX8/PPARγ fusion protein expression caused by 
translocation both enhance unregulated cell growth in 
40% and 30% of subjects, respectively7, and are ex-
pressed in follicular thyroid cancers.
Hereditary conditions
Familial non-medullary thyroid carcinoma
tC is probably among the cancers with highest he-
reditary predisposition1, however, more than 90% is 
sporadic in nature due to somatic genetic alterations8. 
Approximately 3% to 9% of tC is familial non-med-
ullary thyroid carcinoma (FnMtC) with PtC as the 
most common histologic subtype (85-91%), followed 
by FtC (6-10%), AtC (1.6%), and hurthle cell type 
carcinoma (htC)9,10. FnMtC is nonsyndromic in 
95% of cases. As opposed to the sporadic type, familial 
PtC has more aggressive course, with early metasta-
ses, higher recurrence rate, and frequent need for ra-
dioactive iodine treatment11.
Syndromic FNMTC
Five percent of FnMtC cases can be found in in-
herited cancer syndromes. Autosomal dominant he-
reditary syndromes associated with tC are: familial 
adenomatous polyposis, Cowden syndrome, and Car-
ney complex12. Werner syndrome is an autosomal re-
cessive disease with high incidence of neoplasms, such 
as tC12. diagnosing a hereditary syndrome is impor-
tant in order to detect other potentially affected family 
members and associated diseases12.
Medullary thyroid cancer
MtC is a neuroendocrine tumor present in ap-
proximately 3-5% of incidentally found tC arising 
from parafollicular C cells commonly found in the up-
per thyroid poles which secrete calcitonin. Sporadic 
MtC is more frequent than hereditary MtC. only 
around 50% of sporadic MtCs have somatic RET 
mutations, while nearly all cases of familial MtC 
(FMtC), multiple endocrine neoplasia 2A (Men2A), 
and multiple endocrine neoplasia 2B (Men2B) have 
germ line mutations in the Ret proto-oncogene. it 
was discovered that 18-80% of sporadic MtCs have 
somatic mutations of HRAS, KRAS, or rarely NRAS 
genes13, 14.
The familial form of MtC is present in 20-25% of 
cases and is usually a component of Men2A or 2B, or 
a part of FMtC syndrome. Mutations of the Ret 
proto-oncogene, situated on chromosome 10q11.2, are 
responsible for almost all cases of hereditary MtC 
(FMtC), predominantly located in codons within ex-
ons 10,11,13-1612. Penetrance of MtC is close to 
100% when Ret germline mutation is present. Me-
n2A is characterized by bilateral medullary carcinoma 
or C cell hyperplasia (CCh), pheochromocytoma, and 
hyperparathyroidism15. in Men2B, FMtC is associ-
ated with marfanoid habitus, mucosal neuromas, gan-
glioneuromatosis, and pheochromocytoma. in these 
inherited types of MtC, cancers often develop during 
childhood with an earlier progression. in hereditary 
MtC, C cell hyperplasia precedes cancer growth and 
probably represents clonal proliferation of multiple 
transformed progenitor cells12.
















Thyroid imaging with iodine 131
iodine deficiency 













MtC-Medullary thyroid cancer; FnMtC-Familial non-medul-
lary thyroid cancer; BMi-body mass index
Tatjana Bogović Crnčić et al. Risk factors for thyroid cancer
68 Acta Clin Croat, Vol. 59, (Suppl. 1) 2020
Estrogen
The role of estrogen in development of thyroid 
cancer is still a matter of debate in numerous epide-
miological studies. Some studies showed that exoge-
nous estrogen increases the risk, while early loss of 
ovarian estrogen lowers the risk for thyroid cancer. 
Many experimental studies performed so far have 
demonstrated that estradiol behaves as stimulator for 
either benign or malignant tumors. on the other hand, 
hormone therapy was associated with very low or no 
risk for thyroid cancer16.
Radiation exposure
ionizing radiation interacts with dnA, causing 
dnA strand breaks in sensitive sites and somatic mu-
tations, consequently inducing carcinogenesis, and is 
therefore the most-established risk factor for tC. 
damaged, but also non-irradiated, adjacent bystander 
cells show genomic instability. The effect of ionizing 
radiation is especially harmful in children, since thy-
roid tissue is very radiosensitive at an early age1.
Mechanisms of radiation damage
Several types of chromosomal rearrangements oc-
cur in tC, which are common in other radiation-asso-
ciated tumors as well. it has been shown that experi-
mentally exposing human thyroid cells to ionizing ra-
diation can induce Ret/PtC rearrangement17. on 
the other hand, point mutations involving BRAF and 
RAS genes which are common in the general popula-
tion are rare in radiation-related tumors1. After the 
Chernobyl accident, most early cases were solid papil-
lary thyroid cancers with Ret PtC-3 rearrangements 
suggesting radiation damage, while later cases were 
classic PtC with Ret-PtC-1 rearrangements. oth-
er types of Ret rearrangements and some BRAF re-
arrangements were noticed only in a small number of 
Chernobyl papillary thyroid cancers1.
Medical and dental diagnostics have increased thy-
roid exposure to radiation18. Approximately 30% of all 
Ct scans include the head and neck region, exposing 
the thyroid19 in particular, which is especially radiosen-
sitive1. it is known that children exposed to radiation 
in this part of the body frequently develop PtC, which 
was also demonstrated by the Chernobyl experi-
ence20,21. Radiotherapy for head and neck malignancies 
is also a source of thyroid irradiation. it has also been 
demonstrated that dental X-rays could represent risk 
factor for tC in adult age22. 
Thyroid imaging with iodine 131
So far, imaging with radioiodine in a diagnostic 
setting is not correlated with higher incidence of tC, 
but radioiodine treatment, including larger doses for 
Graves’ disease, might correlate with long-term cancer 
genesis in a variety of organs, although the risk seems 
to be quite low23. in a meta-analysis from hieu et al., it 
was concluded that the use of radioiodine for hyper-
thyroidism increased the risk of tC (RR 1.99, 95% Ci: 
0.92-1.33), and a dose effect was also observed for the 
thyroid at doses >1 Gy24.
Iodine intake
iodine deficiency significantly influences thyroid 
function, since a decrease in the level of thyroid hor-
mones causes a consequent rise in thyroid stimulating 
hormone (tSh) secretion, which is a major growth 
stimulating factor for thyroid follicular cells. Therefore, 
chronic milder iodine deficiency may also be a risk fac-
tor for FtC1, although the exact mechanism is still 
unknown. it is believed that long-term tSh stimula-
tion and BRAF mutations in PtC could be involved 
in the mechanism25. According to the literature, iodine 
intake might have a role in tC subtype distribution 
with more follicular cancers in iodine-deficient and 
predominantly papillary cancers in iodine replete re-
gions26. For example, after radioiodine exposure down-
wind of Chernobyl, it was noted that tC incidence 
was higher among children from iodine-deficient ar-
eas1 than in those that were iodine rich27.
Thyroid stimulating hormone (TSH)
it seems that growth factors, primarily iGF-i and 
insulin, have an important role in thyroid cell growth 
stimulation mediated by tSh1. The expression of tSh 
receptors is maintained in well-differentiated thyroid 
cancers, enabling improved survival of patients treated 
with suppressive doses of levothyroxine. A fourfold in-
crease of tC incidence as well as higher risk for ad-
vanced disease stage was found in patients whose tSh 
levels were in the upper quartile compared with those 
in the lower quartile of normal values28. There is evi-
dence that tSh renders thyroid cells in mice suscep-
tible to BRAF-induced transformation, probably 
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through the cyclic adenosine monophosphate (cAMP) 
signaling pathway29.
Autoimmunity
There have been only a few studies about the rela-
tionship between tC and Graves’ disease1, but those 
available suggest an increased risk30. The incidence of 
hashimoto’s thyroiditis (ht) and tC has also in-
creased in the past two decades, suggesting a possible 
correlation. Several underlying mechanisms have been 
described. higher tSh levels in patients with autoim-
mune thyroid disease stimulate follicular proliferation, 
thus promoting the development of PtC31. Further-
more, histologically proven follicular epithelial dyspla-
sia in the form of scattered microfollicles without col-
loid and irregularly shaped follicles in ht has been 
observed. Genesis of tC could also be induced with 
production of proinflammatory cytokines and oxida-
tive stress in autoimmune thyroiditis32. There are also 
several similarities between ht and PtC in cytologi-
cal and immunomarker profiles33. Surgical series ana-
lyzing thyroidectomy results showed a risk for coexis-
tent PtC34. on the other hand, studies using fine 
needle aspiration cytology specimens showed no sig-
nificant increase of PtC in patients with ht35. Pa-
tients who have had systemic lupus erythematosus for 
many years have found to have a higher risk of devel-
oping tC, while hydroxychloroquine therapy could be 
a protective factor36.
Thyroid nodules
it is not certain whether the prevalence of tC is 
different in thyroid glands with a single nodule com-
pared to multinodular goiter4. The general opinion is 
that patients with multiple thyroid nodules have the 
same risk of malignancy as those with solitary nodules. 
There have been studies showing that tC is less fre-
quent in multinodular goiter than in single thyroid 
nodule, although it appears to be true in the iodine-
deficient population only37. 
Environmental pollutants
Studies investigating cancer risk factors associated 
with environmental pollutants have provided interest-
ing results. Some industrialized food additives, such as 
nitrates from cured meat and some vegetables, can 
compete with iodine uptake, potentially alter thyroid 
function38,39, and induce thyroid cancer4. A study by 
Ward et al. has shown that above-average nitrate levels 
in drinking water resources are also associated with an 
increased risk of thyroid cancer40. in recent decades, 
environmental pollutants which may act as either 
genotoxic or nongenotoxic carcinogens, such as asbes-
tos, benzene, formaldehyde, pesticides, and many oth-
ers, have been present4. Polybrominated diphenyl 
ethers (PBdes) that are used in building materials, 
electronics, furnishings, motor vehicles, airplanes, plas-
tics, and textiles may induce abnormal thyroid cell pro-
liferation, favoring a precancerous state41.
Lifestyle and diet
Many studies have tried to establish a relationship 
between dietary habits and tC, but the results are still 
inconclusive. A population-based case-control study 
conducted in 2010-2011 showed negative correlation 
between diet patterns rich in fruits and vegetables and 
tC risk, especially among women aged 50 or older42. 
A positive correlation was observed between the con-
sumption of cruciferous plants (i.e. brussel sprouts and 
cabbage) and the risk of tC. it has also been found 
that above-average consumption of fruits like oranges 
and lemons was associated with tC risk. other fruit 
and vegetables intake in general showed a significantly 
decreased risk of tC43. Physical activity has been sug-
gested to influence thyroid cancer risk4 by improving 
dnA repair ability, reducing body fat content, lower-
ing resistance to insulin, and altering circulating in-
flammatory factors44. on the other hand, a cohort 
study by Schmid et al. showed no association between 
physical activity and tC risk45.
The results of a pooled analysis of five prospective 
studies suggested that cigarette smoking reduces the 
risk for PtC and probably FtC in 30-40% of sub-
jects46. Smoking can lower the levels of tSh47 and has 
an anti-estrogenic effect, which can result in a reduced 
risk of tC48.
A hospital-based case-control study in korea 
showed that female patients with positive family his-
tory, higher BMi, non-smokers, non-drinkers, and 
with lower monthly income, had higher risk for tC 
growth49.
Body weight
The prevalence of PtC was only associated with 
high BMi (body mass index) in men, while there was 
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no statistical difference in women. When multiple risk 
factors were included in the analysis (younger age, 
higher serum tSh and lower fasting blood glucose 
level, smaller nodule diameter, and multifocality), 
obese individuals had a significantly higher risk for 
malignancy compared with patients with normal 
weight. Advanced tnM stage in patients with higher 
BMi was observed in older men. Most of the obesity 
was associated with disruptions in insulin metabolism. 
insulin-like growth factor1 (iGF-1), which has struc-
tural homology to insulin, binds to the iGF-1 receptor 
and behaves like a potent growth factor that stimulates 
malignant transformation, tumor progression, and me-
tastasis50.
Discussion
Thyroid cancer incidence has significantly in-
creased in recent years. The reason for this growing 
number worldwide is still unknown and most likely 
multifactorial. it is thought that the increased inci-
dence is in great part the result of general screening 
and wide availability of thyroid sonography and aspi-
ration biopsies detecting a higher number of small 
thyroid tumors1. however, according to many authors, 
the rising tC incidence cannot be explained solely by 
higher quality screening and detection, so other risk 
factors have been widely investigated51. Among the 
various studied factors, exposure to ionizing radiation 
of the head and neck region in childhood is a well-es-
tablished tC risk factor5,20,21, but increased exposure to 
radiation in general might also contribute4. Many 
studies, summarized and reviewed in this article, have 
focused on other possible risk factors, such as chromo-
somal and genetic alterations, iodine intake, tSh lev-
el, autoimmune thyroid disease, gender, estrogen, obe-
sity, lifestyle changes, and environmental pollut-
ants52,53,54. The results are currently inconclusive, some-
times even controversial, and there is a possibility that 
yet undiscovered carcinogens, especially during intra-
uterine life or early childhood, might be responsible 
for increased tC incidence. epigenetic changes might 
also influence thyroid function or induce carcinogenic 
changes within the thyroid.
Since tC incidence was found to be higher in io-
dine-deficient areas1,27, it is important to encourage 
studies investigating iodine intake in the population, 
especially in children and pregnant women, and to 
promote regular iodine supplementation where appro-
priate. Additionally, the influence of other already rec-
ognized risk factors for cancer development should be 
further explored in the context of tC manifestation. 
The impact of geographical, socioeconomic, ethnic, 
and cultural aspects could also be of interest when tC 
risk factors are studied.
Conclusion
it is evident that further studies are necessary in 
order to investigate the possible risk factors and their 
pathophysiological mechanisms to be able to control 
and potentially slow down the continuous increase of 
thyroid cancer incidence.
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Sažetak
RiZiČni ČiMBeniCi ZA kARCinoM Štitne ŽLiJeZde: Što dAnAS ZnAMo?
T. Bogović Crnčić, M. Ilić Tomaš, N. Girotto i S. Grbac Ivanković
etiologija karcinoma štitnjače, kao najčešćeg endokrinog karcinoma intenzivno se istražuje, budući da je njegova inciden-
cija zadnjih desetljeća u stalnom porastu, prvenstveno na račun diferenciranog papilarnog karcinoma. Jedan od glavnih razlo-
ga porasta incidencije je zasigurno dostupna i kvalitetna dijagnostika karcinoma u ranoj fazi, međutim, uočava se i porast 
broja većih tumora, što upućuje na zaključak da vjerojatno postoje i drugi uzroci. U ovom radu izloženi su rezultati brojnih 
istraživanja usmjerenih na ispitivanje potencijalnih čimbenika rizika koji se dovode u vezu s razvojem karcinoma štitne žli-
jezde, kao što su kromosomske/genske alteracije, unos joda, razina tSh, autoimuna bolest štitnjače, spol, estrogeni, debljina, 
životne navike i čimbenici okoliša, od kojih je jedini dokazani čimbenik rizika izlaganje ionizirajućem zračenju u djetinjstvu. 
Potrebna su daljnja istraživanja s ciljem ispitivanja mogućih čimbenika rizika i njihovih mehanizama djelovanja kako bi se 
moglo učinkovitije kontrolirati i usporiti pojavnost karcinoma štitnjače.
ključne riječi: karcinom štitne žlijezde, rizični čimbenici, ionizirajuće zračenje
